Canopy Growth Past Earnings Performance
Past criteria checks 0/6
Canopy Growth's earnings have been declining at an average annual rate of -21.3%, while the Pharmaceuticals industry saw earnings growing at 1% annually. Revenues have been growing at an average rate of 6.2% per year.
Key information
-21.3%
Earnings growth rate
-11.5%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 6.2% |
| Return on equity | -221.4% |
| Net Margin | -325.8% |
| Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Recent updates
Canopy Growth Is Climbing, But It Won't Last
Mar 22Canopy Growth: Reiterate Strong Sell, Dilutive Offering Likely First Of Many To Come
Feb 06Canopy Growth: Further Implosion Is Now A Matter Of When Not If
Jan 29Avoid Canopy Growth After Failed Equity Sale
Jan 14Canopy Growth (Nasdaq:CGC): Further Dilution Seems Inevitable
Oct 13
Canopy Growth: Getting High
Oct 07Quick Takes: Tesla, Twitter, Carvana & More
Oct 06
Canopy Growth to sell Canadian retail operations, including Tokyo Smoke stores
Sep 27Canopy Growth: BioSteel Sizzles, Everything Else Fizzles
Aug 30What Is Canopy Growth's Stock Outlook After Earnings Miss?
Aug 23Canopy Growth leads cannabis rally as Senator backs compromise legislation
Aug 08Canopy gains 12% to lead Canadian cannabis rally as former Aphria legal chief joins
Aug 02Canopy Growth: Constellation's Investment Goes Up In Smoke
Jul 18Canopy Growth: Bankruptcy Risks Are Growing Like A Weed
Jun 28Canopy Growth: Still Not At Rock Bottom
May 27Can Canopy Growth's Stock Price Recover To $10?
May 04Canopy Growth: Can Wana Save The Day?
Mar 24Canopy Growth: Insight Into Upcoming Q3-2022 Earnings
Feb 08Canopy Growth: 5 Lessons From The Pot Bubble Burst
Dec 27Tilray Vs. Canopy Growth: Which Cannabis Stock Is The Better Buy?
Nov 16Is Canopy Growth Stock A Buy Or Sell Now? Why I'm Getting Bullish
Oct 25Canopy Growth: Cracking The Piggy Bank Again
Oct 15Why Canopy Growth At $18 Is A Great Investment Opportunity
Sep 22Revenue & Expenses BreakdownBeta
How Canopy Growth makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 362 | -1,180 | 352 | 0 |
| 30 Sep 23 | 369 | -1,172 | 386 | 0 |
| 30 Jun 23 | 387 | -1,221 | 427 | 0 |
| 31 Mar 23 | 403 | -3,278 | 455 | 0 |
| 31 Dec 22 | 367 | -3,051 | 401 | 0 |
| 30 Sep 22 | 423 | -2,938 | 445 | 0 |
| 30 Jun 22 | 466 | -2,766 | 517 | 0 |
| 31 Mar 22 | 510 | -310 | 552 | 0 |
| 31 Dec 21 | 557 | -428 | 588 | 0 |
| 30 Sep 21 | 569 | -1,223 | 616 | 0 |
| 30 Jun 21 | 572 | -1,244 | 619 | 0 |
| 31 Mar 21 | 547 | -1,745 | 664 | 0 |
| 31 Dec 20 | 506 | -2,348 | 765 | 0 |
| 30 Sep 20 | 477 | -1,535 | 843 | 0 |
| 30 Jun 20 | 419 | -1,244 | 938 | 0 |
| 31 Mar 20 | 399 | -1,321 | 993 | 0 |
| 31 Dec 19 | 385 | -415 | 961 | -5 |
| 30 Sep 19 | 344 | -256 | 881 | 0 |
| 30 Jun 19 | 291 | -832 | 794 | 0 |
| 31 Mar 19 | 226 | -736 | 642 | 0 |
| 31 Dec 18 | 155 | -398 | 470 | 4 |
| 30 Sep 18 | 94 | -464 | 350 | -1 |
| 30 Jun 18 | 88 | -148 | 199 | 0 |
| 31 Mar 18 | 78 | -67 | 149 | 0 |
| 31 Dec 17 | 70 | -21 | 95 | 0 |
| 30 Sep 17 | 58 | -19 | 66 | 1 |
| 30 Jun 17 | 49 | -13 | 50 | 1 |
| 31 Mar 17 | 40 | -8 | 39 | 1 |
| 31 Dec 16 | 30 | -1 | 29 | 2 |
| 30 Sep 16 | 24 | -7 | 25 | 1 |
| 30 Jun 16 | 18 | -8 | 21 | 1 |
| 31 Mar 16 | 13 | -3 | 17 | 1 |
| 31 Dec 15 | 8 | 0 | 13 | 0 |
| 30 Sep 15 | 6 | 1 | 11 | 0 |
| 30 Jun 15 | 3 | -5 | 10 | 0 |
| 31 Mar 15 | 2 | -7 | 8 | 0 |
| 31 Dec 14 | 1 | -9 | 7 | 0 |
| 30 Sep 14 | 1 | -7 | 5 | 0 |
Quality Earnings: CGC is currently unprofitable.
Growing Profit Margin: CGC is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: CGC is unprofitable, and losses have increased over the past 5 years at a rate of 21.3% per year.
Accelerating Growth: Unable to compare CGC's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: CGC is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (-13.2%).
Return on Equity
High ROE: CGC has a negative Return on Equity (-221.44%), as it is currently unprofitable.